HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by McGill, T. J. Articles by LaVail, M. M. Search for Related Content PubMed PubMed Citation Articles by McGill, T. J. Articles by LaVail, M. M.

Intraocular CNTF Reduces Vision in Normal Rats in a Dose-Dependent Manner

¹From the Canadian Centre for Behavioural Neuroscience, The University of Lethbridge, Lethbridge, Alberta, Canada; the ²Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada; the ³Beckman Vision Center, University of California, San Francisco, California; the ⁴Department of Ophthalmology and ⁵Powell Gene Therapy Center, University of Florida College of Medicine, Gainesville, Florida; the ⁶Moran Eye Center, University of Utah Health Sciences Center, Salt Lake City, Utah; and the ⁷Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon.

PURPOSE. CNTF is a neuroprotective agent for retinal degenerations that can cause reduced electroretinogram (ERG) amplitudes. The goal of the present study was to determine the effects of intraocular delivery of CNTF on normal rat visual function.

METHODS. Full-field scotopic and photopic ERG amplitudes and spatial frequency thresholds of the optokinetic response (OKR) of adult Long-Evans rats were measured before and after intravitreous injection of CNTF or subretinal delivery of adenoassociated virus-vectored CNTF (AAV-CNTF) into one eye. Visual acuity was also measured by using the Visual Water Task in AAV-CNTF-injected animals. Multiunit luminance thresholds were recorded in the superior colliculus after CNTF injection, and the eyes were examined histologically.

RESULTS. In eyes injected with a high dose of CNTF, ERG amplitudes and OKR thresholds measured through CNTF-injected eyes were decreased by 45% to 70% within 6 days after injection. ERG amplitudes had begun to recover by 21 days, whereas OKR thresholds only began to recover after 56 days. Neither OKR thresholds nor ERG amplitudes fully recovered until 90 to 100 days. When measured in the superior colliculus at 2 weeks after CNTF injection, luminance thresholds were elevated by 0.35 log units. In AAV-CNTF-injected eyes, OKR thresholds, and visual acuity were reduced by approximately 50% for at least 6 months, and scotopic and photopic ERG b-waves were reduced by 30% to 50%. Photoreceptor loss occurred in the injected regions in some of the eyes. By contrast, comparison of dose-response analysis with a dose-response study of light damage strongly suggests that therapeutic doses of CNTF exist that do not suppress ERG responses.

CONCLUSIONS. Intraocular delivery of CNTF, which preserves photoreceptors in animal models of retinal degeneration, impairs visual function in normal rats at very high doses, but not at lower doses that still provide protection from constant light damage.

This article has been cited by other articles:

				S. Wang, S. Girman, B. Lu, N. Bischoff, T. Holmes, R. Shearer, L. S. Wright, C. N. Svendsen, D. M. Gamm, and R. D. Lund Long-term Vision Rescue by Human Neural Progenitors in a Rat Model of Photoreceptor Degeneration Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3201 - 3206. [Abstract] [Full Text] [PDF]